Fig. 5From: Polymeric nanomedicines for the treatment of hepatic diseasesStrategies for targeting nanomedicines loaded with various cargoes to the liver. Nanomedicines first enter the liver by passive targeting, and then are internalized by liver cells through ligand-mediated endocytosis (active targeting)Back to article page